Treatment of non-small cell lung cancer with brain metastasis

Abstract

Wang Xiaolei, Liu Deze, Liu Weiwei, Jia Lin, Wang Min. Treatment of non-small cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2015, 42(6): 455-457.

［1］ Kanner AA, Bokstein F, Blumenthal DT, et al. Surgical therapies in brain metas tasis［J］. Semin Oncol, 2007, 34(3): 197-205. ［2］ Ammircati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidecebasedclinical practice guideline［J］. J Neurooncol, 2010, 96(1): 85-96. ［3］ Mahmood U, Kwok Y, Regine WF, et al. Wholebrain irradiation for patients with brain metastases still the standard of car［J］. Lancet Oncol, 2010, 11(3): 221-222. ［4］ Minniti G, Salvati M, Muni R, et al. Stereotacti radiosurgery plus wholebrain radiotherapy for treatment of multiople metastases from nonsmall cell lung cancer ［J］. Anticancer Res, 2010, 30(7): 3055-3061. ［5］ Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brainradiotherapy for brain metastases［J］. J Neurooncol, 2013, 113(3): 459-465. ［6］陈秀军, 肖建平, 李祥攀, 等. 立体定向放疗与全脑放疗在多发脑转移瘤治疗中的作用分析［J］. 中华放射肿瘤学杂志, 2012, 21(1): 1-5. ［7］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinom［J］. Neuro Oncol, 2012, 14(4): 491-495. ［8］ Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metastases from nonsmall cell lung cancer［J］. Lung Cancer, 2010, 68(2): 264-268. ［9］ Ortuzar W, Hanna N, Pennella E, et al. Brain metastases as the primary site of relapse in two randomized phase pemetrexed trials in advanced nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(1): 24-30. ［10］ Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as firstline chemotherapy for advanced nonsmallcell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase Ⅱ trial (GFPC07-01)［J］. Ann Oncol, 2011, 22(11): 2466-2470. ［11］ Dinglin XX, Huang Y, Liu H, et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patientswith brain metastases of lung adenocarcinoma: a singlearmphase Ⅱ clinical trial［J］. J Neurooncol, 2013, 112(3): 461-466. ［12］ Chargari C, Pacaut C, Le Moulec S, et al. First assessment of wholebrain radiation therapy combined with pemetrexedbased chemotherapy in non-smallcell lung carcinoma: data on safety and efficacy［J］. Anticancer Drugs, 2013, 24(7): 736-742. ［13］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma［J］. Neuro Oncol, 2012, 14(4): 491-495. ［14］ Cortot AB, Geriniere L, Robinet G, et al. Phase Ⅱ trial of temozolomideand cisplatin followed by whole brain radiotherapy in non small cell lung cancer patients with brain metastases: a GlotGFPC study［J］. Ann Oncol, 2006, 17 (9): 1412-1417. ［15］ Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced nonsmall cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib［J］. Clin Cancer Res, 2010, 16(23): 5873-5882. ［16］ Wu YL, Zhou C, Cheng Y, et al. Aphase Ⅱ study (CTONG0803) of erlotinib as secondline treatment in advanced nonsmall cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after firstline chemotherapy (CT)［J］. J Clin Oncol, 2011, 29(1): 7605. ［17］ Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation［J］. Lung Cancer, 2012, 77(3): 556-560. ［18］ Welsh JW, Komaki R, Amini A, et al. Phase Ⅱ study of erlotinib with concurrent wholebrain radiation therapy for patients with brain metastases from nonsmall cell lung cancer［J］. J Clin Oncol, 2013, 31(7): 895-902. ［19］ Ettinger DS, Akerley W, Borghaei H, et al. Nonsmall cell lung cancer, version 2.2013［J］. J Natl Compr Canc Netw, 2013, 11(6): 645-653. ［20］ Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial［J］. Lancet, 2004, 363(4): 1665-1672.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.

Treatment of non-small cell lung cancer with brain metastasis

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments